Please login to the form below

Not currently logged in
Email:
Password:

GSK's H1N1 vaccine gains EU approval

GlaxoSmithKline has confirmed that it has been granted a marketing authorisation by the European Commission for its H1N1 vaccine

GlaxoSmithKline (GSK) has confirmed that it has been granted a marketing authorisation for Pandemrix, its H1N1 vaccine, from the European Commission.

Jean Stéphenne, president of GlaxoSmithKline Biologicals, said: "Following the Commission's approval we expect to commence shipments of Pandemrix to European governments from next week [w/c October 5]."

The European Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion and recommended approval of Pandemrix on September 25. Trials of the vaccine began in August and demonstrated that after one dose the vaccine can provide a strong immune response that exceeds the immunogenic criteria defined by international licensing authorities for a pandemic influenza vaccine.

1st October 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...